Grace Therapeutics
Most recent annual filing: 2026-06-18
- GRCE resubmission manufacturing pathway filinglate 2027GRCE resubmission manufacturing pathway filing, late 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (1 active programs)
Discontinued (2)
- betamethasone — Ataxia Telangiectasia · In June 2026, determined not to resume internal development funding under current operating plan; IPR&D asset impairment recognized
- bupivacaine — Postherpetic Neuralgia · In June 2026, determined not to resume internal development funding under current operating plan; IPR&D asset impairment recognized
Biotech Distilled coverage (7)
- 2026-08-06 UPDATE: Grace Therapeutics (GRCE) - The Raise Prints at $2.10 🔒 Paid
- 2026-07-28 UPDATE: Grace Therapeutics (GRCE) - The Type A Answer: Two Factories, No Date 🔒 Paid
- 2026-06-18 UPDATE: Grace Therapeutics (GRCE) - The Pipeline Gets Euthanized and the Auditor Rings the Bell 🔒 Paid
- 2026-04-28 UPDATE: Grace Therapeutics (GRCE) - The CRL Autopsy and the Smart Money Exit 🔒 Paid
- 2026-04-24 UPDATE: Grace Therapeutics (GRCE) - The Silent Killer Strikes: Grace Gets a CRL 🔒 Paid
- 2026-02-14 UPDATE: Grace Therapeutics (GRCE) – The Float Shrinks as the Smart Money Parks for PDUFA 🔒 Paid
- 2026-01-26 Grace Therapeutics (GRCE): Scientific Deep Dive for GTx-104 and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.